Shionogi has expanded its partnership with its Alzheimer’s drug development partner Tetra Therapeutics, giving an option for a buyout of the US biotech ahead of a key trial milestone.
Shionogi’s Mulpleo for severely low levels of blood platelets caused by liver disease is to be made available to NHS patients across the UK after authorities in England and Scotland said it
A trial of Roche’s successor to flu medicine Tamiflu has met its goal in a phase 3 trial, with results showing that the new drug Xofluza is well tolerated in children with the flu.
